


Cenegenics New York is excited to announce a major step forward in our comprehensive evaluation of cardiovascular health with the acquisition of the [VENDYS Endothelix](#) device that measures endothelial function.


The endothelium is the inner lining of blood vessels. Its function is to protect the lining of blood vessels from damage. The first stage in the process is called atherosclerosis (hardening of the arteries or plaque). Endothelial dysfunction is considered to be the earliest stage of atherosclerosis. Unlike atherosclerosis, endothelial or vascular dysfunction is reversible with proper treatment. [Read more....](#)

Advanced Screening for Heart Disease at Cenegenics New York
Joseph Bosiljevac, MD, PhD, FACS
Cenegenics Elite Health



At Cenegenics New York, we currently employ [CIMT](#), a specialized ultrasound of the carotid arteries, as part of our evaluation of cardiovascular risk. CIMT not only detects plaque, but also measures the thickness of the artery wall. Thickening of the artery wall is an early sign of developing vascular disease and is directly related to your risk of heart attack and stroke.

Now, using the Endothelix test, we can actually measure endothelial function non-invasively in just 15 minutes. This augments our current CIMT testing which looks directly at the structure of the blood vessels. Measuring both structure and function gives us a great deal of information regarding our patients' risk for heart attack and stroke.



While the CIMT allows for relatively early detection of vascular disease, changes in CIMT occur slowly over years. The Endothelix device allows for even earlier detection of developing vascular disease. Combining the information from both studies, we can develop strategies to

prevent the formation of plaque, rather than dealing with the consequences (heart attack, stroke, sudden death) once the process is well advanced. An additional advantage of the device is that we can measure a patient's response to various treatments directed at improving endothelial function, even if they already have some level of atherosclerosis.

Cardiovascular disease is the number one killer of both men and women. It kills more people than all forms of cancer combined. Over 50% of people who have a cardiovascular event (heart attack, stroke, sudden cardiac death) have been previously classified as low to intermediate risk using traditional risk factors. Many who suffer a heart attack have normal cholesterol levels, eat a healthy diet and exercise. These tools give us the opportunity to improve these dismal statistics.

At Cenegenics New York, heart health is a major focus. We continue to employ innovative technologies that can help us reduce our patients' risk for heart attack, stroke and sudden cardiac death.

For more information about the Endothelix test, contact our office at 646.963.9711.

[VENDYS -- Endothelial Function Measurement Explained](#)